Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody
Xianmin Meng, Peipei Wang, Yanqing Xiong, Yijun Wu, Xiaoyan Lin, Song Lu, Ruowan Li, Bei Zhao, Jing Liu, Shaoqing Zeng, Liyan Zeng, Yan Wu, Yan Lü, Jinchao Zhang, Datao Liu, Shuhai Wang, Hongzhou Lu
Abstract
ClinicalTrials.gov identifier: NCT04627584.
Topics & Concepts
ImmunogenicityMonoclonal antibodyVirologyTolerabilityPharmacokineticsCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Medicine2019-20 coronavirus outbreakAntibodyPharmacologyImmunologyInfectious disease (medical specialty)Adverse effectOutbreakDiseaseInternal medicineSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing